VivoSim Labs/$VIVS
1D1W1MYTD1Y5YMAX
About VivoSim Labs
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
- Ticker
- $VIVS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15
- Headquarters
- San Diego, United States
- Website
- vivosim.ai
VivoSim Labs Metrics
BasicAdvanced
$4.2M
-
-$3.77
1.47
-
Price and volume
Market cap
$4.2M
Beta
1.47
52-week high
$5.30
52-week low
$0.26
Average daily volume
7.1M
Financial strength
Current ratio
1.704
Quick ratio
0.898
Total debt to equity
-13.47
Interest coverage (TTM)
-944.25%
Profitability
EBITDA (TTM)
-11.137
Gross margin (TTM)
-3,641.07%
Net profit margin (TTM)
-11,016.07%
Operating margin (TTM)
-10,116.96%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-89.50%
Return on equity (TTM)
-343.10%
Valuation
Price to revenue (TTM)
8.336
Price to book
-0.39
Price to tangible book (TTM)
-0.39
Price to free cash flow (TTM)
-0.092
Free cash flow yield (TTM)
-1,084.36%
Free cash flow per share (TTM)
-3.094
Growth
Revenue change (TTM)
-21.13%
Earnings per share change (TTM)
238.53%
3-year revenue growth (CAGR)
-36.86%
10-year revenue growth (CAGR)
-25.29%
3-year earnings per share growth (CAGR)
-46.69%
10-year earnings per share growth (CAGR)
-28.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.